Volume 14 Issue 1
Jan.  2023
Turn off MathJax
Article Contents
Branch of Organ Transplantation of Chinese Medical Association. Clinical technical operation specification of kidney transplantation for autosomal dominant polycystic kidney disease (2022 edition)[J]. ORGAN TRANSPLANTATION, 2023, 14(1): 24-30. doi: 10.3969/j.issn.1674-7445.2023.01.003
Citation: Branch of Organ Transplantation of Chinese Medical Association. Clinical technical operation specification of kidney transplantation for autosomal dominant polycystic kidney disease (2022 edition)[J]. ORGAN TRANSPLANTATION, 2023, 14(1): 24-30. doi: 10.3969/j.issn.1674-7445.2023.01.003

Clinical technical operation specification of kidney transplantation for autosomal dominant polycystic kidney disease (2022 edition)

doi: 10.3969/j.issn.1674-7445.2023.01.003
  • Received Date: 2022-10-21
    Available Online: 2023-01-17
  • Publish Date: 2023-01-15
  • Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disease and one of the most common causes for end-stage renal disease (ESRD). Kidney transplantation is the optimal renal replacement therapy for ADPKD patients complicated with ESRD. Currently, scholars at home and abroad have a certain controversy about whether polycystic kidney resection is necessary in ADPKD patients before kidney transplantation, and the criteria and methods for polycystic nephrectomy also differ. To further standardize the clinical technical operation of kidney transplantation in ADPKD patients, experts in organ transplantation organized by Branch of Organ Transplantation of Chinese Medical Association formulated this specification from the aspects of diagnosis of ADPKD, indications and contraindications of kidney transplantation for ADPKD, preoperative evaluation and treatment, polycystic nephrectomy, and postoperative management, etc.

     

  • Corresponding authors: Tian Ye, Email: tianye166@126.com
  • loading
  • [1]
    ANSELMO A, IARIA G, PELLICCIARO M, et al. Native nephrectomy in patients with autosomal dominant polycystic kidney disease evaluated for kidney transplantation[J]. Transplant Proc, 2019, 51(9): 2914-2916. DOI: 10.1016/j.transproceed.2019.08.010.
    [2]
    CORNEC-LE GALL E, ALAM A, PERRONE RD. Autosomal dominant polycystic kidney disease[J]. Lancet, 2019, 393(10174): 919-935. DOI: 10.1016/S0140-6736(18)32782-X.
    [3]
    BEVILACQUA M, GRADIN S, WILLIAMS J, et al. The BC ADPKD network: a comprehensive provincial approach to support specialized and locally delivered multidisciplinary ADPKD care[J]. Can J Kidney Health Dis, 2021, 8: 20543581211035218. DOI: 10.1177/20543581211035218.
    [4]
    PEI Y, OBAJI J, DUPUIS A, et al. Unified criteria for ultrasonographic diagnosis of ADPKD[J]. J Am Soc Nephrol, 2009, 20(1): 205-212. DOI: 10.1681/ASN.2008050507.
    [5]
    IRAZABAL MV, RANGEL LJ, BERGSTRALH EJ, et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials[J]. J Am Soc Nephrol, 2015, 26(1): 160-172. DOI: 10.1681/ASN.2013101138.
    [6]
    AKBARI P, NASRI F, DENG SX, et al. Total kidney volume measurements in ADPKD by 3D and ellipsoid ultrasound in comparison with magnetic resonance imaging[J]. Clin J Am Soc Nephrol, 2022, 17(6): 827-834. DOI: 10.2215/CJN.14931121.
    [7]
    RAJ S, SINGH RG, DAS P. Mutational screening of PKD1 and PKD2 in Indian ADPKD patients identified 95 genetic variants[J]. Mutat Res, 2020, 821: 111718. DOI: 10.1016/j.mrfmmm.2020.111718.
    [8]
    HATEBOER N, V DIJK MA, BOGDANOVA N, et al. Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group[J]. Lancet, 1999, 353(9147): 103-107. DOI: 10.1016/s0140-6736(98)03495-3.
    [9]
    MALLAWAARACHCHI AC, LUNDIE B, HORT Y, et al. Genomic diagnostics in polycystic kidney disease: an assessment of real-world use of whole-genome sequencing[J]. Eur J Hum Genet, 2021, 29(5): 760-770. DOI: 10.1038/s41431-020-00796-4.
    [10]
    NIELSEN ML, LILDBALLE DL, RASMUSSEN M, et al. Clinical genetic diagnostics in Danish autosomal dominant polycystic kidney disease patients reveal possible founder variants[J]. Eur J Med Genet, 2021, 64(4): 104183. DOI: 10.1016/j.ejmg.2021.104183.
    [11]
    CHAPMAN AB, DEVUYST O, ECKARDT KU, et al. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference[J]. Kidney Int, 2015, 88(1): 17-27. DOI: 10.1038/ki.2015.59.
    [12]
    LUBENNIKOV AE, PETROVSKⅡ NV, KRUPINOV GE, et al. Bilateral nephrectomy in patients with autosomal dominant polycystic kidney disease and end-stage chronic renal failure[J]. Nephron, 2021, 145(2): 164-170. DOI: 10.1159/000513168.
    [13]
    PIERRE M, MOREAU K, BRACONNIER A, et al. Unilateral nephrectomy versus renal arterial embolization and technique survival in peritoneal dialysis patients with autosomal dominant polycystic kidney disease[J]. Nephrol Dial Transplant, 2020, 35(2): 320-327. DOI: 10.1093/ndt/gfz200.
    [14]
    ZHOU C, GU Y, MEI C, et al. Dialysis modality and mortality in polycystic kidney disease[J]. Hemodial Int, 2018, 22(4): 515-523. DOI: 10.1111/hdi.12673.
    [15]
    DARIUS T, BERTONI S, DE MEYER M, et al. Simultaneous nephrectomy during kidney transplantation for polycystic kidney disease does not detrimentally impact comorbidity and graft survival[J]. World J Transplant, 2022, 12(5): 100-111. DOI: 10.5500/wjt.v12.i5.100.
    [16]
    GADELKAREEM RA, ABDELGAWAD AM, MOHAMMED N. Simultaneous kidney transplantation and ipsilateral native nephrectomy in patients with autosomal dominant polycystic kidney disease[J]. World J Transplant, 2022, 12(9): 310-312. DOI: 10.5500/wjt.v12.i9.310.
    [17]
    XU J, D'SOUZA K, LAU NS, et al. Staged versus concurrent native nephrectomy and renal transplantation in patients with autosomal dominant polycystic kidney disease: a systematic review[J]. Transplant Rev (Orlando), 2022, 36(1): 100652. DOI: 10.1016/j.trre.2021.100652.
    [18]
    TSAI TY, CHEN CH, WU MJ, et al. Outcomes of kidney transplantation in patients with autosomal dominant polycystic kidney disease: our experience based on 35-years follow-up[J]. Diagnostics (Basel), 2022, 12(5): 1174. DOI: 10.3390/diagnostics12051174.
    [19]
    PRUDHOMME T, BOISSIER R, HEVIA V, et al. Native nephrectomy and arterial embolization of native kidney in autosomal dominant polycystic kidney disease patients: indications, timing and postoperative outcomes. a systematic review[J]. Minerva Urol Nephrol, 2022, DOI: 10.23736/S2724-6051.22.04972-2[Epub ahead of print].
    [20]
    HAN JH, JEONG SH, YUK HD, et al. Safety and feasibility of synchronous unilateral nephrectomy and contralateral heminephrectomy for extremely severe autosomal dominant polycystic kidney disease: techniques and outcome[J]. Investig Clin Urol, 2022, 63(3): 341-349. DOI: 10.4111/icu.20210461.
    [21]
    JEAN RA, ALEXANDRE M, YOO PS. Kidney transplantation with and without native nephrectomy for polycystic kidney disease: results of the national inpatient sample and the rationale for a 2-staged procedure[J]. J Am Coll Surg, 2018, 226(6): 1079-1084. DOI: 10.1016/j.jamcollsurg.2017.11.021.
    [22]
    PRABHU M, DAMLE NA, RAY A, et al. 18F-FDG PET/CT in cyst infection in autosomal dominant polycystic kidney disease[J]. Indian J Radiol Imaging, 2020, 30(1): 102-104. DOI: 10.4103/ijri.IJRI_469_18.
    [23]
    常染色体显性多囊肾病临床实践指南专家委员会. 中国常染色体显性多囊肾病临床实践指南(第二版)[J]. 临床肾脏病杂志, 2019, 19(4): 227-235. DOI: 10.3969/j.issn.1671-2390.2019.04.001.

    Expert Committee on Clinical Practice Guidelines for Autosomal Dominant Polycystic Kidney Disease. Chinese clinical practice guide for autosomal dominant polycystic kidney disease[J]. J Clin Nephrol, 2019, 19(4): 227-235. DOI: 10.3969/j.issn.1671-2390.2019.04.001.
    [24]
    张磊, 张健, 田野, 等. 后腹腔镜联合Gibson切口多囊肾切除一期同种异体肾移植术3例报道并文献复习[J]. 临床和实验医学杂志, 2017, 16(8): 747-749. DOI: 10.3969/j.issn.1671-4695.2017.08.007.

    ZHANG L, ZHANG J, TIAN Y, et al. Simultaneous retroperitoneoscopic nephrectomy and kidney transplantation using Gibson incision with autosomal dominant polycystic kidney disease: report of three cases and literature review[J]. J Clin Exp Med, 2017, 16(8): 747-749. DOI: 10.3969/j.issn.1671-4695.2017.08.007.
    [25]
    TSUKAMOTO S, URATE S, YAMADA T, et al. Comparative efficacy of pharmacological treatments for adults with autosomal dominant polycystic kidney disease: a systematic review and network meta-analysis of randomized controlled trials[J]. Front Pharmacol, 2022, 13: 885457. DOI: 10.3389/fphar.2022.885457.
    [26]
    QIAN Q, DU H, KING BF, et al. Sirolimus reduces polycystic liver volume in ADPKD patients[J]. J Am Soc Nephrol, 2008, 19(3): 631-638. DOI: 10.1681/ASN.2007050626.
    [27]
    WU LZ, WENG YQ, LING YX, et al. A Web of Science-based scientometric analysis about mammalian target of rapamycin signaling pathway in kidney disease from 1986 to 2020[J]. Transl Androl Urol, 2021, 10(3): 1006-1017. DOI: 10.21037/tau-20-1469.
    [28]
    中华医学会器官移植学分会. 器官移植免疫抑制剂临床应用技术规范(2019版)[J]. 器官移植, 2019, 10(3): 213-226. DOI: 10.3969/j.issn.1674-7445.2019.03.001.

    Branch of Organ Transplantation of Chinese Medical Association. Technical specifcation for clinical application of immunosuppressive agents in organ transplantation (2019 edition)[J]. Organ Transplant, 2019, 10(3): 213-226. DOI: 10.3969/j.issn.1674-7445.2019.03.001.
    [29]
    JUNG Y, IRAZABAL MV, CHEBIB FT, et al. Volume regression of native polycystic kidneys after renal transplantation[J]. Nephrol Dial Transplant, 2016, 31(1): 73-79. DOI: 10.1093/ndt/gfv227.
    [30]
    YAMAMOTO T, WATARAI Y, KOBAYASHI T, et al. Kidney volume changes in patients with autosomal dominant polycystic kidney disease after renal transplantation[J]. Transplantation, 2012, 93(8): 794-798. DOI: 10.1097/TP.0b013e318246f910.
    [31]
    MAHAJAN S, NARAYANAN V, BHATIA V, et al. Anesthetic considerations for a patient with autosomal dominant polycystic kidney disease, having a ruptured intracranial aneurysm for endovascular coiling: a case report[J]. Asian J Neurosurg, 2022, 17(2): 379-382. DOI: 10.1055/s-0042-1750811.
    [32]
    ECONIMO L, ZENI L, CORTINOVIS R, et al. ADPKD and intracranial aneurysms: indications for screening, follow-up and clinical management[J]. G Ital Nefrol, 2021, 38(5): 2021-vol5.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)

    Article Metrics

    Article views (658) PDF downloads(140) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return